DE68921436T2 - Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt. - Google Patents

Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.

Info

Publication number
DE68921436T2
DE68921436T2 DE68921436T DE68921436T DE68921436T2 DE 68921436 T2 DE68921436 T2 DE 68921436T2 DE 68921436 T DE68921436 T DE 68921436T DE 68921436 T DE68921436 T DE 68921436T DE 68921436 T2 DE68921436 T2 DE 68921436T2
Authority
DE
Germany
Prior art keywords
cataracts
treatment
carboxylic acids
aliphatic
carbons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68921436T
Other languages
English (en)
Other versions
DE68921436D1 (de
Inventor
William H Garner
Larry A Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE68921436D1 publication Critical patent/DE68921436D1/de
Publication of DE68921436T2 publication Critical patent/DE68921436T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
DE68921436T 1988-12-09 1989-12-11 Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt. Expired - Fee Related DE68921436T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28276788A 1988-12-09 1988-12-09

Publications (2)

Publication Number Publication Date
DE68921436D1 DE68921436D1 (de) 1995-04-06
DE68921436T2 true DE68921436T2 (de) 1995-08-10

Family

ID=23083041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921436T Expired - Fee Related DE68921436T2 (de) 1988-12-09 1989-12-11 Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.

Country Status (6)

Country Link
US (1) US5399573A (de)
EP (1) EP0373002B1 (de)
JP (1) JPH02202818A (de)
AT (1) ATE119038T1 (de)
DE (1) DE68921436T2 (de)
ES (1) ES2068253T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0494405T3 (da) * 1991-01-10 1996-11-18 Transcend Therapeutics Inc Anvendelse af thiazolidin-4-carboxylatderivater til behandling af lungesygdomme
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
US20030130324A1 (en) * 1993-11-19 2003-07-10 Johnston W. Mcavoy Method for preventing or controlling cataract
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5925658A (en) * 1995-03-02 1999-07-20 Sankyo Company, Limited Optically active thiazolidinone derivative
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US5686450A (en) * 1995-06-07 1997-11-11 Alcon Laboratories, Inc. Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
US5576278A (en) * 1995-06-07 1996-11-19 Alcon Laboratories, Inc. Stable liquid enzyme compositions and methods of use
ES2156633T3 (es) * 1996-03-25 2001-07-01 Alcon Lab Inc Derivados del acido tiazolidina-4-carboxilico como agentes citoprotectores.
WO2017201318A1 (en) 2016-05-18 2017-11-23 Sound Pharmaceuticals Incorporated Treatment of meniere's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526789A (en) * 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4351826A (en) * 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4474817A (en) * 1980-02-29 1984-10-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
JPS5718615A (en) * 1980-07-07 1982-01-30 Senjiyu Seiyaku Kk Anticataract agent
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US5091421A (en) * 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors

Also Published As

Publication number Publication date
EP0373002B1 (de) 1995-03-01
EP0373002A2 (de) 1990-06-13
DE68921436D1 (de) 1995-04-06
ES2068253T3 (es) 1995-04-16
US5399573A (en) 1995-03-21
JPH02202818A (ja) 1990-08-10
EP0373002A3 (de) 1991-07-31
ATE119038T1 (de) 1995-03-15

Similar Documents

Publication Publication Date Title
DE68921436D1 (de) Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.
DE69129921T2 (de) Behandlung von Katarakt mit 15-keto-Prostaglandinderivaten
RU98117628A (ru) Замещенные производные тиазолидиндиона, способ их получения, фармкомпозиция
KR920000754A (ko) 환식아미드 유도체
NO179638C (no) Analogifremgangsmåte for fremstilling av tiazolderivater
TW206970B (de)
DE3750464D1 (de) Pharmazeutisches Präparat zur Behandlung des Katarakts.
DK707988A (da) Fremgangsmaade til at haemme virus
NO833528L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenyl-cyklobutan-derivater
DE69019404T2 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
HUT50464A (en) Process for producing phenothiazin derivatives
DK384485D0 (da) 1,6-naphthyridinderivater med kardilaterende virkning
EA200000448A1 (ru) Новые полиморфные формы ципамфиллина
ES457988A1 (es) Un procedimiento de preparacion de un derivado de fenilpipe-razina.
ES2054829T3 (es) Antibioticos del grupo mureidomicina, su preparacion y su empleo.
FR2663026B1 (fr) Derives de [(1-arylpyrrolidin-2-yl) methyl] piperazine, leur preparation et leur application en therapeutique.
EP0369776A3 (de) Verwendung einer Zusammensetzung, die organisch gebundenes Germanium enthaltet, zur Herstellung von Arzneimitteln zur Behandlung von AIDS
ATE58141T1 (de) 1-hydroxy-5-oxo-5h-pyrido(3,2-a>-phenoxazin-3carbons|ureester.
DE69026098D1 (de) Organogermaniumderivate enthaltende Zubereitungen zur therapeutischen Verwendung
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
NO167382C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-hydroxy-4-(substituerte alkenyl)cyklohexancarboxylsyrer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee